JAMA Network Open
April 10, 2024
Akhila Yerubandi, Catherine Harrington, Joshua Caballero et al.
80 citations
Importance Psilocybin has been studied in the treatment of depression and anxiety disorders. Clinical studies have mainly focused on efficacy, with systematic reviews showing favorable efficacy; however, none have primarily focused on psilocybin safety. Objective To evaluate the acute adverse effects of psilocybin at therapeutic doses in the treatment of depression and anxiety. Data Sources...
iScience
April 9, 2024
Ram Harari, Ipsita Chatterjee, Dmitriy Getselter et al.
20 citations
Psilocybin, and its metabolite psilocin, induces psychedelic effects through activation of the 5-HT2A receptor. Psilocybin has been proposed as a treatment for depression and anxiety but sometimes induces anxiety in humans. An understanding of mechanisms underlying the anxiety response will help to better develop therapeutic prospects of psychedelics. In the current study, psilocybin induced an...
March 1, 2024
Aspen Allred, Aspen Allred
Social Anxiety Disorder (SAD) is a debilitating mental health condition characterized by an overwhelming fear and anxiety of social rejection that can lead to chronic patterns of social behavioral avoidance. Despite the existence of traditional efficacious treatments, a significant number of individuals either do not respond to treatment or experience a recurrence of symptoms over extended...
Current Psychiatry Research and Reviews
January 21, 2024
Payal Ghosh, Debjeet Sur
1 citation
: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...
Behavioral Neuroscience
January 18, 2024
Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh et al.
22 citations
Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on...
Cancer Research
January 16, 2024
Kelsey Klute, Lou Lukas, Soonjo Hwang et al.
2 citations
Abstract Background: Psychological distress is a common reaction to a cancer diagnosis and its treatment. Distress impacts quality of life, adherence to treatment, decision making and survival. Patients with pancreatic adenocarcinoma (PDAC) experience exceptionally high rates of psychological distress, most commonly depression, anxiety and suicidality. Psilocybin, a serotonergic psychedelic...
Psicologia e Saúde em Debate
January 10, 2024
Leonardo Hercílio Florêncio Silva, Júnia Aparecida Laia Da Mata, Sabrina Stefanello et al.
Psilocybin is a natural substance with hallucinogenic properties that has recently been used in the field of health. It is an alkaloid that, when associated with psychotherapy, has shown benefits in the treatment of depression and anxiety. This study aims to analyze the current state of knowledge about the psychological effects of psilocybin in patients with terminal cancer. The method used was...
2024
Albert Lehr
Psychedelics are a class of drugs that can occasion similar changes in conscious ex- periences mediated via the G-protein coupled Serotonin 2A receptor. These changes vary from slight distortions in perceptions to pseudohallucinations and the experienced cessation of a personal self distinct from and necessary for conscious experience, known as ego-dissolution. Psychedelics produce positive...
Neuroscience Applied
2024
Isabelle Straumann, Friederike Holze, Laura Ley et al.
24 citations
Psilocybin is being studied for its therapeutic potential in various mental health disorders, such as depression, anxiety, and addiction. Initial studies suggested that psilocybin is generally safe when used under controlled conditions, but more research is needed to better understand its safety profile. We report safety pharmacology data from a pooled analysis of three randomized crossover...
Research Square
December 28, 2023
Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al.
1 citation
preprint
Abstract Background: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin...